HIND

8-K - Vyome Holdings, Inc (0001427570) (Filer)

10-Q - Vyome Holdings, Inc (0001427570) (Filer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.

Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved

DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)

Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)

10-K - Vyome Holdings, Inc (0001427570) (Filer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026 Livechain, Inc. ("Livechain") (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, d/b/a, Humanyze ("Humanyze"), a rapidly emerging human resources data and analytics company. The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued to Remus by Humanyze. Through th

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key antici

Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product Vyome Holdings, Inc. ("Vyome" or the "Company") (NASDAQ:HIND) announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds ("MFW"). The Company accomplished this funding need using its existing At-The-Market ("ATM") facility. Additional details on this funding are as follows: All additional funds were raised on January 27, 2026. 1,089,045 common sha

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a positive Phase 2 is estimated to be USD 455 million Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis commissioned by Vyome and conducted by Destum Pa

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Vyome Board completes review of strategic alternatives for LICH, executes critical first step in building a scalable, standalone business Vyome Holdings, Inc. ("Vyome') (NASDAQ:HIND) announced its subsidiary, LiveChain, Inc. ("Livechain" or "LICH") (OTC Markets: LICH) has executed a binding letter of intent ("LOI") with Remus Capital, a leading AI-focused venture capital firm, that will put LiveChain in control of the Humanyze brand, intellectual property, and other know-how of Sociometric Solutions, Inc. DBA Humanyze ("Humanyze"), a rapidly emerging AI-enabled human resources data and analytics company. The LOI contemplates that, as consideration for the transaction, LICH shall issue s

VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002). Patient-reported impact of bad smell or malodor on quality of life (secondary endpoint) improved significantly (P = 0.0256), as did wound pain reduction (P = 0.002) VT-1953 was well-tolerated, with no new safety concerns observed. Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity. Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced the final r

424B3 - Vyome Holdings, Inc (0001427570) (Filer)

Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. "I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can signi

8-K - Vyome Holdings, Inc (0001427570) (Filer)

4 - Vyome Holdings, Inc (0001427570) (Issuer)

3 - Vyome Holdings, Inc (0001427570) (Issuer)

4 - Vyome Holdings, Inc (0001427570) (Issuer)